BioInvent has developed several antibody candidates that are currently in clinical development, both as monotherapy and in combination with current standard treatments. The two leading drug candidates BI-1206 and BI-1808 is being tested in phase I/IIa studies for the treatment of Non-Hodgkin's lymphoma (NHL) and solid tumors.
The company's research suggests that both of these first-in-class immunomodulatory antibodies have the potential to enhance the efficacy of standard treatment such as various immunotherapies and improve the outcome of cancer treatment.
Three other products, BT 001, BI-1607 and BI-1910, is being tested in early clinical studies as potential treatments for several types of cancer. In addition, the Lund-based biotechnology company has also out-licensed five clinical projects to other companies.
Clinical data to be presented at ASCO 2024
BioInvent has been selected to present two posters for BI-1808 and BI-1206 at American Society for Clinical Oncology annual congress (ASCO 2024) in Chicago, Illinois from May 31 to June 4.
The two poster presentations will report initial combination data from the Phase I/IIa study of BI-1808 in combination with Keytruda for MDS, as well as an update from the monotherapy arm. Combination data from the Phase I/IIa study of BI-1206 in combination with Keytruda for the treatment of patients with solid tumors will also be presented.
“These presentations mark the start of a data-rich year for BioInvent and build on the promising initial results from each program reported in 2023. We continue to advance the clinical development of both BI-1808 and BI-1206 and look forward to seeing the first Phase II data for BI-1808 and BI-1206 in late 2024.” – Martin Welschof, CEO BioInvent
Progress during Q1
BioInvent has also published its interim report for the first quarter. The company ended the quarter with a solid financial position of SEK 1219 million in cash and investments, which the CEO Martin Welschof commented in the report:
– BioInvent remains well-funded with funds to achieve the communicated milestones expected during the year. An active first quarter has provided a strong start to the year and we have much to look forward to in the coming months.
In January, the rights to immuno-oncology target structures were reacquired from the partner Exelixis, followed by a supply agreement with AstraZeneca in February where BI-1206 will be evaluated in a Phase IIa triple combination study where Calquence is added to the BI-1206 + rituximab mix in patients with NHL.
In March, BioInvents knew the partner CASI Pharmaceuticals announce positive preliminary efficacy data from a Phase I dose escalation and expansion study of BI-1206 in combination with rituximab. In a press release, CASI noted that the study showed impressive signs of clinical efficacy, with four partial responses and one complete response in eight evaluable patients. Read more here.
A month later, BioInvent signed a new, fourth, clinical collaboration and supply agreement with MSDThe agreement concerns an evaluation of BioInvent's BI-1910 in combination with MSD's Keytruda in the second part of the phase I/IIa study for the treatment of solid tumors.
- This is our fifth product in clinical trials, demonstrating the capacity of BioInvent's technology to identify novel, therapeutic, first-in-class targets., stated Martin Welschof.